By Fineline Cube 
Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture and ablation surgery robots founded in 2018, has submitted its initial public offering (IPO) prospectus to the Hong Kong Stock Exchange, planning to list on the bourse. The company has established a comprehensive intelligent medical robot product matrix centered on “percutaneous puncture, precision treatment,” featuring multiple China-first and global-first innovations across its surgical robotics and organ preservation platforms.
Company Profile & Core Product Portfolio
| Item | Detail |
|---|---|
| Company | Guangdong True Health Medical Technology Development Co., Ltd. |
| Founded | 2018 |
| IPO Status | Prospectus filed with Hong Kong Stock Exchange |
| Core Focus | Percutaneous puncture surgery and ablation surgery robots |
| Strategic Theme | “Percutaneous puncture, precision treatment” |
| Geographic Focus | China with global expansion potential |
Core Surgical Robot Platforms
- TH-S1: NMPA Class III approved for lung/abdominal solid organ puncture; expanding to retroperitoneal lesions
- TH-S: NMPA Class III approved for lung/abdominal solid organ puncture
- TH-S Pro: NMPA Class III approved for lung/abdominal solid organ puncture
- TH-SA: Registration application submitted May 2025 for lung/abdominal solid organ puncture
Regulatory Milestones & Product Pipeline
Approved Products
- TH-S1, TH-S, TH-S Pro: All hold Class III medical device registration certificates from China’s National Medical Products Administration (NMPA) for percutaneous puncture surgeries of solid organs in lungs and abdomen
- TH-X MW & TH-X HMW: Percutaneous microwave ablation surgery robots approved for liver tumor treatment
- TH-P Series: Miniaturized percutaneous puncture surgery robot approved for lung and abdominal puncture procedures
Development Pipeline
- MW150: Microwave ablation therapy instrument
- TH-X Cryo: Cryoablation robot
- THLS KI300 & TH-LS LU100: Ex vivo organ preservation and evaluation systems
- Dedicated Consumables: Full range compatible with surgical robots and organ preservation systems
Market Opportunity & Strategic Positioning
True Health operates in China’s rapidly expanding surgical robotics market, which is projected to reach ¥20–25 billion ($2.8–3.5 billion) annually by 2028. The company’s focus on percutaneous procedures addresses a significant unmet need:
- Minimally Invasive Advantage: Reduces patient recovery time, hospital stays, and complications compared to open surgery
- Precision Enhancement: Robotic assistance improves accuracy in targeting small lesions and complex anatomical locations
- Physician Training: Addresses shortage of highly skilled interventional radiologists through robotic assistance
- Cost-Effectiveness: Lower capital expenditure compared to large surgical robot systems while maintaining clinical benefits
“This IPO represents a critical milestone in our mission to revolutionize minimally invasive surgery in China and globally,” said Dr. Chen Ming, Founder and Chief Executive Officer of True Health Medical. “Our comprehensive portfolio of percutaneous surgery robots, combined with our organ preservation systems, creates a unique integrated platform that addresses the full spectrum of precision intervention needs.”
Competitive Differentiation
True Health’s strategic advantages include:
- Regulatory Leadership: Multiple Class III NMPA approvals in a highly regulated segment
- Technology Integration: Seamless compatibility between robots, ablation systems, and consumables
- Clinical Breadth: Coverage across puncture, microwave ablation, cryoablation, and organ preservation
- Innovation Pipeline: Continuous development of next-generation miniaturized and specialized platforms
The company’s TH-SA platform, pending regulatory approval, represents the next evolution in percutaneous robotics with enhanced capabilities for complex procedures.
Industry analysts view True Health as well-positioned to capture significant market share in China’s surgical robotics sector, with potential for international expansion leveraging its China-first innovations and cost-competitive manufacturing model.
Forward‑Looking Statements
This brief contains forward-looking statements regarding IPO plans, regulatory approvals, and market opportunities for True Health Medical. Actual results may vary based on Hong Kong Stock Exchange review, regulatory decisions, and competitive dynamics.-Fineline Info & Tech